Abstract:Sex differences in the prognostic role of achieving target doses of heart failure (HF) medications. In females TD of RASI/ARNI was less likely achieved and achieving TD of RASI/ARNI was not associated with lower mortality/morbidity as compared with lower dose, whereas in males increasing doses of RASI/ARNI were associated with lower mortality/morbidity. For beta‐blockers there were no differences in doses achieved and higher doses were associated with better outcome regardless of sex. ARNI, angiotensin receptor–neprilysin inhibitor; CV, cardiovascular; HFrEF, heart failure with reduced ejection fraction; HHF, hospitalization for heart failure; IQR, interquartile range; RASI, renin–angiotensin system inhibitor; TD, target dose Aims Guidelines recommend target doses (TD) of heart failure (HF) with reduced ejection fraction (HFrEF) medications regardless of sex. Differences in pharmacokinetics and pharmacodynamics may explain heterogeneity in treatment response, adverse reactions, and tolerability issues across sexes. The aim of this study was to explore sex‐based differences in the association between TD achievement and mortality/morbidity in HFrEF. Methods and results Patients with HFrEF and HF duration ≥6 months registered in the Swedish HF Registry between May 2000 and December 2020 (follow‐up until December 2021) were analysed. Treatments of interest were renin–angiotensin system inhibitors (RASI) or angiotensin receptor–neprilysin inhibitors (ARNI), and beta‐blockers. Multivariable Cox regression models were performed to explore the risk of cardiovascular mortality or hospitalization for HF across dose categories in females versus males. A total of 17 912 patients were analysed (median age 77.0 years, interquartile range [IQR] 70.0–83.0), 29% were female. Over a median follow‐up of 1.33 years (IQR 0.29–3.22), for RASI/ARNI there was no significant difference in outcome for females achieving 50–99% versus 100% of TD (hazard ratio 0.92, 95% confidence interval 0.83–1.03), whereas males showed a gradual lowering in risk together with the achievement of higher % of TD (p‐interaction = 0.030). For beta‐blockers the achievement of TD was associated with the lowest risk of outcome regardless of sex. Conclusions Our findings suggest that females and males might differently benefit from the same dose of RASI/ARNI, and do represent a general call for randomized controlled trials to consider sex‐specific up‐titration schemes when testing HFrEF treatments in need of up‐titration.

Sex differences in the cardiovascular effects of GnRH analogues

Comparative Cardiovascular Safety of Gonadotropin-releasing Hormone Antagonists and Agonists Among Patients Diagnosed with Prostate Cancer: A Systematic Review and Meta-analysis of Real-world Evidence Studies

Cardiovascular Toxicity of Androgen Deprivation Therapy

Abstract 12107: Cardiovascular Outcomes Associated With Gonadotropin-Releasing Hormone Antagonists vs Gonadotropin-Releasing Hormone Agonists for Prostate Cancer Treatment: A Meta-Analysis of Randomized Controlled Trials

Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice

Adverse cardiovascular effect following gonadotropin-releasing hormone antagonist versus GnRH agonist for prostate cancer treatment: A systematic review and meta-analysis

Androgen deprivation therapy and side effects: are GnRH antagonists safer?

Does Exist a Differential Impact of Degarelix Versus LHRH Agonists on Cardiovascular Safety? Evidences From Randomized and Real-World Studies

Sex-specific considerations in cardiovascular drug therapy

Current and Potential Application of GnRH Agonists in Gynecologic Practice

Cardiovascular Risk Profile in Prostate Cancer Patients Treated with GnRH Agonists versus Antagonists: An Italian Real-World Analysis

Cardiovascular risk in ADT recipients: does the type of ADT matter?

Sex and sex steroids as determinants of cardiovascular risk

Individualized medicine: Sex, hormones, genetics, and adverse drug reactions

Genomic and non-genomic effects of androgens in the cardiovascular system: clinical implications

Cardiovascular alteration and treatment of hypertension

Sex differences in the prognostic role of achieving target doses of heart failure medications: Data from the Swedish Heart Failure Registry

Sex-Related Effects on Cardiac Development and Disease

A systematic review and meta-analysis of cardiovascular disease risk with degarelix and GnRH agonists in prostate cancer

Gonadotropin-releasing hormone antagonist associated with lower cardiovascular risk compared with gonadotropin-releasing hormone agonist in prostate cancer: A nationwide cohort and in vitro study

Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan